Uptravi

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
28-06-2022
Opinber matsskýrsla Opinber matsskýrsla (PAR)
19-07-2017

Virkt innihaldsefni:

Selexipag

Fáanlegur frá:

Janssen Cilag International NV

ATC númer:

B01AC27

INN (Alþjóðlegt nafn):

selexipag

Meðferðarhópur:

Antithrombotic agents

Lækningarsvæði:

Hypertension, Pulmonary

Ábendingar:

Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.,

Vörulýsing:

Revision: 13

Leyfisstaða:

Authorised

Leyfisdagur:

2016-05-12

Upplýsingar fylgiseðill

                                33
B. PACKAGE LEAFLET
34
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
UPTRAVI 200 MICROGRAM FILM-COATED TABLETS
UPTRAVI 400 MICROGRAM FILM-COATED TABLETS
UPTRAVI 600 MICROGRAM FILM-COATED TABLETS
UPTRAVI 800 MICROGRAM FILM-COATED TABLETS
UPTRAVI 1,000 MICROGRAM FILM-COATED TABLETS
UPTRAVI 1,200 MICROGRAM FILM-COATED TABLETS
UPTRAVI 1,400 MICROGRAM FILM-COATED TABLETS
UPTRAVI 1,600 MICROGRAM FILM-COATED TABLETS
selexipag
READ ALL OF THIS LEAFLET CAREFULLY BEFORE TAKING THIS MEDICINE BECAUSE
IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you have any side effects, talk to your doctor or nurse. This
includes any possible side effects
not listed in this leaflet (see section 4).
WHAT IS IN THIS LEAFLET
1.
What Uptravi is and what it is used for
2.
What you need to know before you take Uptravi
3.
How to take Uptravi
4.
Possible side effects
5.
How to store Uptravi
6.
Contents of the package and other information
1.
WHAT UPTRAVI IS AND WHAT IT IS USED FOR
Uptravi is a medicine that contains the active substance selexipag. It
acts on blood vessels in a similar
way to the natural substance prostacyclin, making them relax and
widen.
Uptravi is used for the long-term treatment of pulmonary arterial
hypertension (PAH) in adult patients
insufficiently controlled with other types of medicines for PAH known
as endothelin receptor
antagonists and phosphodiesterase type 5 inhibitors. Uptravi can be
used on its own if the patient is not
a candidate for these medicines.
PAH is high blood pressure in the blood vessels that carry blood from
the heart to the lungs (the
pulmonary arteries). In people with PAH, these arteries narrow, so the
heart has to work harder to
pump blood through them. This may cause people to feel tired, dizzy,
short of breath, or experience
other sy
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Uptravi 200 microgram film-coated tablets
Uptravi 400 microgram film-coated tablets
Uptravi 600 microgram film-coated tablets
Uptravi 800 microgram film-coated tablets
Uptravi 1,000 microgram film-coated tablets
Uptravi 1,200 microgram film-coated tablets
Uptravi 1,400 microgram film-coated tablets
Uptravi 1,600 microgram film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Uptravi 200 microgram film-coated tablets
Each film-coated tablet contains 200 micrograms of selexipag.
Uptravi 400 microgram film-coated tablets
Each film-coated tablet contains 400 micrograms of selexipag.
Uptravi 600 microgram film-coated tablets
Each film-coated tablet contains 600 micrograms of selexipag.
Uptravi 800 microgram film-coated tablets
Each film-coated tablet contains 800 micrograms of selexipag.
Uptravi 1,000 microgram film-coated tablets
Each film-coated tablet contains 1,000 micrograms of selexipag.
Uptravi 1,200 microgram film-coated tablets
Each film-coated tablet contains 1,200 micrograms of selexipag.
Uptravi 1,400 microgram film-coated tablets
Each film-coated tablet contains 1,400 micrograms of selexipag.
Uptravi 1,600 microgram film-coated tablets
Each film-coated tablet contains 1,600 micrograms of selexipag.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet
Uptravi 200 microgram film-coated tablets
Round, 7.3 mm diameter, light-yellow, film-coated tablets,with “2”
debossed on one side.
Uptravi 400 microgram film-coated tablets
3
Round, 7.3 mm diameter, red, film-coated tablets with “4” debossed
on one side.
Uptravi 600 microgram film-coated tablets
Round, 7.3 mm diameter, light-violet, film-coated tablets with “6”
debossed on one side.
Uptravi 800 microgram film-coated tablets
Round, 7.3 mm diameter, green, film-coated tablets with “8”
debossed on one side.
Uptravi 1,000 microgram film-coated tablets
Round, 7.3 mm diameter, orange, film-coated tablets with “10”
debo
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 28-06-2022
Vara einkenni Vara einkenni búlgarska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla búlgarska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 28-06-2022
Vara einkenni Vara einkenni spænska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla spænska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 28-06-2022
Vara einkenni Vara einkenni tékkneska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla tékkneska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 28-06-2022
Vara einkenni Vara einkenni danska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla danska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 28-06-2022
Vara einkenni Vara einkenni þýska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla þýska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 28-06-2022
Vara einkenni Vara einkenni eistneska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla eistneska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 28-06-2022
Vara einkenni Vara einkenni gríska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla gríska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 28-06-2022
Vara einkenni Vara einkenni franska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla franska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 28-06-2022
Vara einkenni Vara einkenni ítalska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla ítalska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 28-06-2022
Vara einkenni Vara einkenni lettneska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla lettneska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 28-06-2022
Vara einkenni Vara einkenni litháíska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla litháíska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 28-06-2022
Vara einkenni Vara einkenni ungverska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla ungverska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 28-06-2022
Vara einkenni Vara einkenni maltneska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla maltneska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 28-06-2022
Vara einkenni Vara einkenni hollenska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla hollenska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 28-06-2022
Vara einkenni Vara einkenni pólska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla pólska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 28-06-2022
Vara einkenni Vara einkenni portúgalska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla portúgalska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 28-06-2022
Vara einkenni Vara einkenni rúmenska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla rúmenska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 28-06-2022
Vara einkenni Vara einkenni slóvakíska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 28-06-2022
Vara einkenni Vara einkenni slóvenska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla slóvenska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 28-06-2022
Vara einkenni Vara einkenni finnska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla finnska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 28-06-2022
Vara einkenni Vara einkenni sænska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla sænska 19-07-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 28-06-2022
Vara einkenni Vara einkenni norska 28-06-2022
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 28-06-2022
Vara einkenni Vara einkenni íslenska 28-06-2022
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 28-06-2022
Vara einkenni Vara einkenni króatíska 28-06-2022
Opinber matsskýrsla Opinber matsskýrsla króatíska 19-07-2017

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu